# A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

> **NCT05870917** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- Plasma Cell Leukemia

## Interventions

- **BIOLOGICAL:** anti-BCMA CAR-T

## Key facts

- **NCT ID:** NCT05870917
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2026-06
- **Final completion:** 2027-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870917, "A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05870917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*